Everything tagged "dividend" across the TickerSpark archives.
State Street posted record 1Q26 AUC/A and AUM, with revenue and fee momentum improving across servicing, management, and FX. The stock looks like a disciplined Buy, though valuation already reflects much of the progress.
Citizens Financial Group is improving earnings power through margin expansion, stronger fee income, and a growing private bank. The stock still looks reasonably priced versus its rising earnings outlook.
Elevance Health is working through a Medicaid-driven margin reset, but Q2 results, raised guidance, and Carelon growth point to a resilient earnings recovery. The stock looks attractively valued for a large managed-care platform with scale, cash flow, and multiple growth levers.
U.S. Bancorp is pairing steady core banking growth with a strong fee engine and improving efficiency. The stock looks attractive for balanced investors as earnings expand and valuation remains reasonable.
Abbott is evolving from a defensive healthcare name into a stronger medtech-led compounder, helped by Medical Devices growth and the Exact Sciences deal. Nutrition remains a drag, but the stock looks attractive on weakness rather than at any price.
Marsh & McLennan is executing well across broking and consulting, with 2025 revenue of $26.98B and Q1 2026 growth still running at 8%. The stock looks like a quality compounder, but valuation and leverage keep the upside measured.
Travelers combines elite underwriting, strong capital returns, and a fortress balance sheet, but the stock looks close to fully valued after a strong run. Buy on weakness, with upside constrained unless growth and pricing improve further.
Charles Schwab is turning record client growth, rising managed investing flows, and a stronger balance sheet into a steadier compounder. Valuation is reasonable, but rate sensitivity and cash behavior still matter.
BNY is executing well as a scaled financial infrastructure platform, with strong revenue growth, expanding margins, and raised 2026 guidance. Valuation is no longer cheap, so the stock looks best on pullbacks.
Progressive is pairing rapid policy growth with elite underwriting, making it one of the strongest operators in U.S. auto insurance. The stock still looks attractive, but valuation is no longer cheap after a big run.
BlackRock is using ETF dominance, Aladdin, and private-markets expansion to drive stronger revenue and earnings leverage. Q1 2026 showed powerful inflows, margin expansion, and rising mix quality.
Citigroup is evolving from a restructuring story into a stronger global banking franchise, with Services and Markets driving better growth, leverage, and returns. The stock still trades at a reasonable valuation despite clear operating momentum.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime